Teva Pharmaceutical Industries Long Term Debt 2010-2024 | TEVA

Teva Pharmaceutical Industries long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • Teva Pharmaceutical Industries long term debt for the quarter ending June 30, 2024 was $16.547B, a 11.5% decline year-over-year.
  • Teva Pharmaceutical Industries long term debt for 2023 was $18.161B, a 4.93% decline from 2022.
  • Teva Pharmaceutical Industries long term debt for 2022 was $19.103B, a 11.63% decline from 2021.
  • Teva Pharmaceutical Industries long term debt for 2021 was $21.617B, a 4.9% decline from 2020.
Teva Pharmaceutical Industries Annual Long Term Debt
(Millions of US $)
2023 $18,161
2022 $19,103
2021 $21,617
2020 $22,731
2019 $24,562
2018 $26,700
2017 $28,829
2016 $32,524
2015 $8,358
2014 $8,566
2013 $10,387
2012 $11,712
2011 $10,236
2010 $4,110
2009 $4,311
Teva Pharmaceutical Industries Quarterly Long Term Debt
(Millions of US $)
2024-06-30 $16,547
2024-03-31 $16,584
2023-12-31 $18,161
2023-09-30 $18,495
2023-06-30 $18,698
2023-03-31 $19,668
2022-12-31 $19,103
2022-09-30 $18,497
2022-06-30 $20,363
2022-03-31 $20,840
2021-12-31 $21,617
2021-09-30 $21,037
2021-06-30 $21,602
2021-03-31 $22,288
2020-12-31 $22,731
2020-09-30 $23,515
2020-06-30 $24,616
2020-03-31 $24,473
2019-12-31 $24,562
2019-09-30 $23,812
2019-06-30 $25,955
2019-03-31 $25,834
2018-12-31 $26,700
2018-09-30 $26,816
2018-06-30 $28,965
2018-03-31 $29,450
2017-12-31 $28,829
2017-09-30 $31,971
2017-06-30 $33,806
2017-03-31 $32,694
2016-12-31 $32,524
2016-09-30 $33,179
2016-06-30 $8,036
2016-03-31 $8,619
2015-12-31 $8,358
2015-09-30 $9,516
2015-06-30 $9,496
2015-03-31 $9,391
2014-12-31 $8,566
2014-09-30 $8,818
2014-06-30 $9,122
2014-03-31 $10,244
2013-12-31 $10,387
2013-09-30 $10,061
2013-06-30 $9,925
2013-03-31 $9,938
2012-12-31 $11,712
2012-09-30 $12,688
2012-06-30 $12,625
2012-03-31 $10,157
2011-12-31 $10,236
2011-09-30 $4,365
2011-06-30 $3,920
2011-03-31 $4,877
2010-12-31 $4,110
2010-09-30 $4,740
2010-06-30 $5,071
2010-03-31 $3,463
2009-12-31 $4,311
2009-09-30 $4,302
2009-06-30 $4,718
2009-03-31 $5,063
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $20.902B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00